Drugs /

sgn-b6a

Back to Drugs List

Overview

NCI Definition [1]:
An antibody-drug conjugate (ADC) composed of a humanized antibody targeting integrin beta-6 and conjugated to the microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration, the antibody moiety of anti-integrin beta-6/MMAE ADC SGN-B6A targets and binds to integrin beta-6 on the surface of tumor cells. Following internalization of SGN-B6A and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in integrin beta-6-expressing tumor cells. Integrin beta-6 is a subunit of integrin alpha-V beta-6 (aVb6). Integrin aVb6, a cell adhesion and signaling receptor, is upregulated in certain cancer cell types and has been associated with increased proliferation, migration and invasion of tumor cells.

Clinical Trials

View Clinical Trials for sgn-b6a

Sgn-b6a has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating sgn-b6a, 1 is phase 1 (1 open).

HER2 Deficient Expression and HER2 Negative are the most frequent biomarker inclusion criteria for sgn-b6a clinical trials.

Bladder carcinoma, breast carcinoma, and cervical carcinoma are the most common diseases being investigated in sgn-b6a clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sgn-B6a
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sgn-b6a and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-integrin beta-6/mmae antibody-drug conjugate sgn-b6a, sgnb6a, sgn b6a, anti-integrin beta-6-mmae adc sgn-b6a
NCIT ID [1]:
C172391

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.